目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY
2.2.2 SEGMENT ASSESSMENT METHODOLOGY
2.3 GROWTH FORECAST
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RECESSION IMPACT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 IMPACT OF AI/GEN AI
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 WHOLE GENOME SEQUENCING METHOD
5.9.1.2 16S RNA SEQUENCING METHOD
5.9.1.3 NANOPORE SEQUENCING
5.9.2 COMPLIMENTARY TECHNOLOGIES
5.9.2.1 METATRANSCRIPTOMICS
5.9.2.2 METAGENOMICS
5.9.2.3 METABOLOMICS
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 SAMPLE PREPARATION
5.9.3.2 DATA ANALYSIS
5.9.3.3 LIBRARY SYNTHESIS
5.10 PATENT ANALYSIS
5.11 PIPELINE ANALYSIS
5.12 KEY CONFERENCES & EVENTS 2024-2025
5.13 REGULATORY LANDSCAPE
5.13.1 REGULATORY SCENARIO
5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.14 PORTER’S FIVE FORCES ANALYSIS
5.14.1 THREAT OF NEW ENTRANTS
5.14.2 THREAT OF SUBSTITUTE
5.14.3 BARGAINING POWER OF SUPPLIERS
5.14.4 BARGAINING POWER OF BUYERS
5.14.5 INTENSITY OF COMPETITION RIVALRY
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.13.2 BUYING CRITERIA FOR END USERS
5.16 CASE STUDIES
5.17 INVESTMENT AND FUNDING SCENARIO

6 HUMAN MICROBIOME MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 DRUGS
6.3 PROBIOTICS
6.4 PREBIOTICS
6.5 SYNBIOTICS
*The above segmentation is subject to change during research.

7 HUMAN MICROBIOME MARKET, BY DISEASE
7.1 INTRODUCTION
7.2 INFECTIOUS DIEASES
7.3 GASTROINTESTINAL DISEASES
7.4 ENDOCRINE AND METABOLIC DISORDERS
7.6 OTHER DISEASES (INCLUDES CANCER, AUTOIMMUNE DISORDERS)

9 HUMAN MICROBIOME MARKET, BY TYPE
9.1 INTRODUCTION
9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/ FECAL MICROBIOTIA TRANSPLANTATION (FMT)
9.4 LIVE BIOTHERAPEUTIC PRODUCT
9.5 OTHERS (INCLUDES PEPTIDES, METABOLITES)
*The above inclusions for Other Types segment is subject to change during research.

10 HUMAN MICROBIOME MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOSPITALS AND CLINICS
10.3 LONG-TERM CARE FACILITIES
10.4 OTHER END USERS (SPECIALTY CARE CENTERS, OUTPATIENT CARE CENTERS)
* The above inclusions for Other Types segment is subject to change during research.

11 HUMAN MICROBIOME MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.2.3 RECESSION IMPACT
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 UK
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.3.7 RECESSION IMPACT
11.4 ASIA PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 REST OF ASIA PACIFIC
11.4.7 RECESSION IMPACT
11.5 LATIN AMERICA
11.5.1 BRAZIL
11.5.2 REST OF LATIN AMERICA
11.5.3 RECESSION IMPACT
11.6 MIDDLE EAST
11.6.1 GCC
11.6.1.1 SAUDI ARABIA (KSA)
11.6.1.2 UNITED ARAB EMIRATES (UAE)
11.6.1.3 REST OF GCC
11.6.2 REST OF MIDDLE EAST
11.6.3 RECESSION IMPACT
11.7 AFRICA
11.7.1 RECESSION IMPACT
NOTE 1: REST OF EUROPE INCLUDES SWITZERLAND, RUSSIA, PORTUGAL, POLAND, NETHERLANDS, FINLAND, DENMARK, BELGIUM, AUSTRIA, HUNGARY, ICELAND, IRELAND, NORWAY, AND LUXEMBOURG
NOTE 2: REST OF ASIA PACIFIC INCLUDES BANGLADESH, BHUTAN, NEPAL, SRI LANKA, PHILIPPINES, SINGAPORE, VIETNAM, THAILAND, TAIWAN, CAMBODIA, AND INDONESIA
NOTE 3: REST OF LATIN AMERICA INCLUDES COLOMBIA, ECUADOR, PERU, URUGUAY, CUBA AND CHILE
NOTE 4: REST OF GCC INCLUDES BAHRAIN, KUWAIT, AND OMAN

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
12.3 REVENUE SHARE ANALYSIS (TOP PLAYERS), 2023
12.4 MARKET SHARE ANALYSIS (TOP PLAYERS), 2023
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
12.5.5.1 COMPANY FOOTPRINT
12.5.5.2 REGION FOOTPRINT
12.5.5.3 TYPE FOOTPRINT
12.5.5.4 DISEASE FOOTPRINT
12.5.5.5 PRODUCT FOOTPRINT
12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.6.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
12.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
12.7 COMPETITIVE SCENARIO
12.7.1 DEALS
12.7.2 OTHER DEVELOPMENTS
12.8 BRAND/ PRODUCT COMPARATIVE ANALYSIS
12.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE HUMAN MICROBIOME MARKET

13 COMPANY PROFILES
13.1 KEY COMPANIES
13.1.1 SERES THERAPEUTICS, INC.
13.1.2 FERRING PHARMACEUTICALS
13.1.3 BIOMEBANK
13.1.4 NESTLÉ S.A.
13.1.5 SANOFI
13.1.6 SEED HEALTH,INC
13.1.7 ENTEROME
13.1.8 PENDULUM
13.1.9 QUANTBIOME, INC. (DBA OMBRE)
13.1.10 VEDANTA BIOSCIENCES, INC.
13.1.11 FINCH THERAPEUTICS GROUP, INC.
13.1.12 MAAT PHARMA SA
13.1.13 INTERNATIONAL FLAVORS & FRAGRANCES, INC.
13.1.14 OPTIBIOTX HEALTH PLC
13.1.15 SYNLOGIC, INC.
13.2 OTHER PLAYERS
13.2.1 GUANGZHOU ZHIYI BIOTECHNOLOGY CO., LTD.
13.2.2 AOBIOME
13.2.3 SIOLTA THERAPEUTICS
13.2.4 ALVEOLUS BIO, INC.
13.2.5 MRM HEALTH NV
13.2.6 BIOME INC
13.2.7 SANZYME BILOGICS.
13.2.8 BIOMX
13.2.9 NUBIYOTA
13.2.10 QUORUM INNOVATIONS

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS